Synthesis, biological evaluation and docking studies of 2,3-dihydroquinazolin-4(1H)-one derivatives as inhibitors of cholinesterases by Sarfraz, Muhammad et al.
1 
 
 
 
 
Synthesis, biological evaluation and docking studies of 2,3-dihydroquinazolin-
4(1H)-one derivatives as inhibitors of cholinesterases  
Muhammad Sarfraz 1, Nargis Sultana 1, Umer Rashid 2,*, Muhammad Safwan Akram3, Abdul 
Sadiq4, Muhammad Ilyas Tariq1,** 
1 Department of Chemistry, University of Sargodha, Sargodha, Pakistan 
2 Department of Chemistry, COMSATS Institute of Information Technology, Abbottabad 22060, Pakistan  
3 School of Science & Engineering, Teesside University, Middlesbrough, Tees Valley, UK TS1 3BA 
4 Department of Pharmacy, University of Malakand, Chakdara 18000 Dir (L), Pakistan 
 
  * Corresponding Author at: Department of Chemistry, COMSATS Institute of Information Technology, 
Abbottabad 22060, Pakistan  
Email:  umerrashid@ciit.net.pk 
** Corresponding Author at: Department of Chemistry, University of Sargodha, Sargodha, Pakistan 
Email: tariqmi2000@yahoo.com, dir.m@uos.edu.pk,  
 
 
 
 
 
 
2 
 
 
Abstract: 
In search of potent inhibitors of cholinesterases, we have synthesized and evaluate a number of 
2,3-dihydroquinazolin-4(1H)-one derivatives. The synthetic approach provided an efficient 
synthesis of the target molecules with excellent yield. All the tested compounds showed activity 
against both the enzymes in micromolar range. In many case, the inhibition of both enzymes are 
higher than or comparable to the standard drug galatamine. With the selectivity index of 2.3 for 
AChE, compound 5f can be considered as a potential lead compound with a feature of dual 
AChE/BChE inhibition with IC50 = 1.6±0.10 µM (AChE) and 3.7±0.18 µM (BChE). Binding 
modes of the synthesized compounds were explored by using GOLD (Genetic Optimization for 
Ligand Docking) suit v5.4.1. The computed binding modes of these compounds in the active site 
of AChE and BChE provide an insight into the mechanism of inhibition of these two enzymes. 
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1. Introduction: 
Alzheimer’s disease (AD) is one of the most common Neurodegenerative Disorders (NDs) and is 
considered as the reason for almost 60% of the dementia cases among the persons over 65 years 
of age [1-2]. AD is a multifactorial disorder that is associated with dementia and memory 
impairment. Various pathological hypotheses have been put forth to explain the onset and 
progression of this disease. These include decreased levels of Acetylcholine (ACh) or enhanced 
activities of acetylcholinesterase (AChEs), amyloid-β (Aβ) deposits, tau (τ)-protein aggregation 
and oxidative stress. These all hypotheses are based on the biochemical phenomenon found to be 
happening in the brains of AD patients. Cholinesterases is found to be the only effective therapeutic 
approach for AD up till now [3-5].  
For the symptomatic treatment of Alzheimer’s disease, drug discovery researchers have developed 
multiple cholinesterase inhibitors (ChEI) including newer ChEIs (Phenserine, Tolserine, Esolerine 
and Tesofensine), naturally derived ChEIs (Nelumbo nucifera, Huperzine A, Huperzine B, 
Himatanthus lancifolius and Galangin, Cardanol Derivatives), hybrids (5-(N-Methyl-N-propargyl-
aminomethyl) Quinolin-8-yl Dimethyl Carbamate and 5-(N-Methyl-N-propargylaminomethyl) 
Quinolin-8-yl Ethylmethyl Carbamate, Donepezil-AP2238, Donepezil-Tacrine Hybrids and 
Tacrine-8-hydroxyquinoline Hybrids), and synthetic analogues (N-Alkyl-7-methoxytacrine 
Hydrochlorides, Phenyl-5,6-dimethoxy-1-oxo-2,3-dihydro-1H-2-indenylmethanone Analogues, 
and Ladostigil) and many more which are under preclinical and clinical trials [3, 6-7]. 
Quinazoline, a class of fused pyrimidine consists of very useful nitrogen containing heterocyclic 
moieties which show various biological activities like anticonvulsant and hypnotic, anticancer, 
antimicrobial and antihistaminic, diuretic, antimalarial, antihypertensive, antagonism of ghrelin 
receptor, anti-inflammatory, analgesic and COX-2 inhibitory activities as well as antifungal 
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activities [8-17]. On the basis of substitution pattern on central ring of quinazoline, it can be 
divided into 2-substituted-4(3H)-quinazolinones, 3-substituted-4(3H)-quinazolinones, 2,3-
disubstituted-4(3H)-quinazolinones, 4-substituted-quinazolines and 2,4-disubstituted-4(3H)-
quinazolinones categories [18]. Of these synthesis of 2-substituted quinazolinones have attracted 
the chemists because of their wide range of medicinal and biological properties such as anti-
inflammatory, antihypertensive, antibacterial activity, anticancer and antitumor [19-22]. Li et al 
reported the AChE/BChE inhibition of a series of novel 2-(2-indolyl-)-4(3H)-quinazolines 
derivates in nanomolar range [23]. Uraz et al reported 4(3H)-quinazolinone derivatives as good 
AChE inhibitors [24]. Similarly, highly potent spacer-modified bivalent quinazolinimines were 
reported by Chen et al as inhibitors of AChE/BChE [25].  
Recently, we have reported rational design and synthesis of dihydropyrimidine based dual binding 
site acetylcholinesterase inhibitors [26]. The objective of this study is to discover a new scaffold 
as inhibitor of cholinesterases. Herein, we reported the synthesis and in vitro bioactivity of 2,3-
dihydroquinazolin-4(1H)-one derivatives as inhibitors of cholinesterases.  
2. Results and discussion 
2.1. Chemistry 
Various chemists have attempted synthesis of a variety of quinazoline derivatives with focus on 
synthesis of 2-monosubstituted ones. Very few examples for the synthesis of 2,2-disubstituted 
quinazoline moieties have been recorded in literature due to their low yields, drastic reaction 
conditions and prolonged reaction times. However, in many cases use of catalytic methodologies 
as alternatives to condensation methods have provided many benefits to the scaffold synthesis. 
Catalytic carbonylation, domino reaction, hydrogen transfer process, use of metals such as iridium, 
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rhodium and palladium also provide mild reaction conditions and high yields [27-29]. We tried 
comparatively an inexpensive acid catalysis method for the synthesis of quinazolines. Starting 
from 2-amino benzamide and ketone, we were able to synthesize 2,3-dihydroquinazolin-4(1H)-
one core  under acid catalysis (1ml of HNO3/HCl : 3/1) with excellent yield (Scheme 1).  
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Scheme 1: Synthesis of 2,3-dihydroquinazolin-4(1H)-ones (3a-h) 
The synthesis of target compounds (4a-h) was commenced with reaction of unsubstituted phenyl 
ring of 2,3-dihydroquinazolin-4(1H)-one core (3a-h) with conc. HNO3 in the presence of H2SO4 
(Scheme 2).  
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Scheme 2: Synthesis of dinitro derivatives of 2,3-dihydroquinazolin-4(1H)-ones (4a-h) 
Dibrominated 2,3-dihydroquinazolin-4(1H)-ones (5a-h) were also synthesized by the reaction of 
3a-h with potassium bromate (KBrO3) in acidic medium (Scheme 3). 
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Scheme 3: Synthesis of dibromo derivatives of 2,3-dihydroquinazolin-4(1H)-ones (5a-h) 
In the 1H NMR spectra of 2,3-dihydroquinazolin-4(1H)-ones (3a-h), unsubstituted phenyl ring of 
quinazoline was deduced from their four signals of one proton each, chemical shift values and their 
coupling constants. One 1H-signal as dd (Jortho = 8 Hz and Jmeta = 2Hz), one triplet (Jortho = 8 Hz), 
one multiplet and one doublet (Jortho = 8 Hz) was assigned to protons H-5, H-6, H-7 and H-8 
respectively. 1H-NMR signals with splitting at 1.70-1.74 ppm (doublet, J = 6 Hz) and 1.38-1.78 
(multiplet) were assigned to –CH2 protons of isobutyl / ethyl / propyl substituents at C-2 
respectively. Intrinsic splitting pattern at about 1.85-1.94 (m) and 0.86-0.93 (t, Jortho = 7 Hz) 
corresponds to –CH and -CH3 of ethyl / propyl / isobutyl group respectively. Two broad singlets 
at 5.76-5.87 and 6.81-6.92 ppm were interpreted for the –NH protons at position-1 and 3 of the 
quinazoline ring respectively. 1H-NMR of the series 4a-h and 5a-h were deduced with almost 
same splitting pattern. However, two highly deshielded signals in the range of 9.21-9.23 and 9.22-
9.06 ppm (d, J = 8 Hz) appeared due to the –NO2 groups (4a-h) whereas due to Br substitution 
(5a-h) signals appeared at 7.81-7.89 and 7.38-7.68 (d, J = 8 Hz) for H-5 and H-7 respectively. In 
13C-NMR, a characteristic most downfield signal at 1630-164.6 ppm was interpreted for C-4 
carbonyl group. A relatively upfield signal was C-9 at 143.9-147.2 ppm. While C-10 signal was 
observed at 116.0-119.6 ppm. The quinazoline C-2 was detected at 66.8-72.6 ppm.  
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2.2. XRD 
The structures of the synthesized compounds were also confirmed by single crystal X-ray 
diffraction studies. Crystallographic structures and data of some represented compounds are 
presented in Supplementary information (Figure S1-S3 and in Table S-1 and S-2).  
2.3. In vitro pharmacology 
2.3.1 AChE and BChE inhibition assay 
The inhibitory potency (IC50 values) of the synthesized compounds against AChE (Electrophorus 
electricus) and BChE inhibition (equine serum) was evaluated according to the method [26, 30]. 
The in vitro results and selectivity index for AChE and BChE inhibition are summarized in Table 
1.  
All the synthesized quinazolines showed good to moderate degree of inhibition and the IC50 value 
of some of compounds are in low micromolar range toward both enzymes. In general, a clear trend 
appears that the derivatives with 4-choloropheny group at C-2 position of quinazoline ring (3f, 4f 
and 5f) possess high AChE/BChE inhibitory activity in their respective series of analogues. 
Similarly, compounds with di-isobutyl group (3h, 4h and 5h) also exhibited good inhibition toward 
both enzymes. Compounds 3a-h with unsubstituted phenyl ring are less potent than their dinitro 
(4a-h) and dibromo (5a-h) counterparts.  
Compounds 4f, 4h, 5b, 5f and 5h were more potent AChE inhibitors than the standard drug 
Galantamine with IC50 values in the range of 1.6 µM to 3.9 µM. Amongst the dinitro series (4a-
h), compound 4f emerged as potent compound with IC50 value of 3.8±0.14 µM. Compound 4h 
also exhibited good AChE inhibition (IC50 = 3.9±0.17 µM) comparable to that of 4f. Dibromo 
derivatives (5a-h) emerged as inhibitor as good as their dinitro counterparts. Introduction of 4-
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chlorophenyl group at C-2 position led to potent compound 5f (IC50 = 1.6±0.10 µM). Methyl and 
ethyl substituents at C-2 position did not improve the AChE inhibition. However, replacing these 
substituents by isobutyl /diisobutyl group (5g and 5h) resulted in moderate to good activity.  
To evaluate the selectivity profile, IC50 values of the synthesized compounds toward BChE were 
also determined. As seen from Table 1, with exception of compounds 3f and 3g, all the other 
compounds of subset 3a-h exhibited moderate to very little BChE inhibition. However, the 
compounds of this series have reduced the selectivity for AChE inhibition. Di-isobutyl derivative 
3g has inhibitory selectivity for BChE (SI=0.5). Compounds 3a, 3c-e exhibited very little BChE 
inhibitory activity. Instead, good BChE inhibition was found within the dinitro subset (4a-h) where 
7 out of 8 derivatives were more active than galatamine having IC50 values in the range of 5.3±0.21 
µM to 14.2±0.53 µM. Compound 4h with BChE IC50 value of 5.3±0.21 µM has good inhibitory 
activity (SI=1.3). Dibromo subset (5a-h) is displayed less BChE inhibition than corresponding 
dinitro subset. With the selectivity index of 2.3 for AChE, compound 5f can be considered as a 
potential lead compound as dual AChE / BChE inhibitor with IC50 = 1.6±0.10 µM (AChE) and 
3.7±0.18 µM (BChE).  
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Table 1: In vitro AChE and BChE inhibitory activity of the synthesized compounds 
N
H
NH
O
R1
R2
R3
R4  
Compound R1 R2 R3 R4 
IC50 (µM ±SEM) Selectivity 
Index a eeAChE eqBChE 
3a CH3 CH3 H H 80.3±1.8 97.5±2.40 1.2 
3b CH3 C6H5 H H 24.5±0.70 20.3±0.52 0.8 
3c CH3 CH2CH3 H H 29.4±0.60 58.3±1.74 1.9 
3d CH2CH3 CH2CH3 H H 54.2±1.63 57.9±1.62 1.0 
3e CH3 CH2CH2CH3 H H 31.1±1.08 33.4±0.66 1.0 
3f CH3 4-Cl. C6H4 H H 9.9±0.10 11.2±0.28 1.1 
3g CH3 CH2CH(CH3)2 H H 31.0±0.82 17.9±0.57 0.5 
3h CH2CH(CH3)2 CH2CH(CH3)2 H H 10.4±0.23 23.4±0.63 2.2 
4a CH3 CH3  NO2 NO2 24.4±0.62 21.0±0.70 0.8 
4b CH3 C6H5 NO2 NO2 6.2±0.13 9.9±0.44 1.6 
4c CH3 CH2CH3 NO2 NO2 20.7±0.31 13.9±0.48 0.6 
4d CH2CH3 CH2CH3 NO2 NO2 19.3±0.57 14.2±0.53 0.7 
4e CH3 CH2CH2CH3 NO2 NO2 12.1±0.42 13.3±0.33 1.1 
4f CH3 4-Cl. C6H4 NO2 NO2 3.8±0.14 10.3±0.30 2.7 
4g CH3 CH2CH(CH3)2 NO2 NO2 4.6±0.19 12.2±0.42 2.6 
4h CH2CH(CH3)2 CH2CH(CH3)2 NO2 NO2 3.9±0.17 5.3±0.21 1.3 
5a CH3 CH3 Br Br 25.0±0.90 86.2±3.44 3.4 
5b CH3 C6H5 Br Br 3.5±0.12 6.4±0.21 1.8 
5c CH3 CH2CH3 Br Br 29.4±0.90 22.1±0.88 0.7 
5d CH2CH3 CH2CH3 Br Br 17.9±0.82 16.2±0.40 0.9 
5e CH3 CH2CH2CH3 Br Br 5.4±0.16 23.4±0.58 4.3 
5f CH3 4-Cl. C6H4 Br Br 1.6±0.10 3.7±0.18 2.3 
5g CH3 CH2CH(CH3)2 Br Br 11.2±0.22 18.4±0.64 1.6 
5h CH2CH(CH3)2 CH2CH(CH3)2 Br Br 2.5±0.10 14.2±0.34 5.7 
Galatamine 4.0±0.10 15.0±0.67 3.7 
a Values are expressed as mean ( standard error of the mean of at least three experiments. 
b Selectivity Index = IC50 ratio (BChE/AChE). 
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2.4. Molecular modelling 
2.4.1. Molecular modeling studies on AChE and BChE inhibition 
For designing the drug and to understand the molecular mechanism of AD, the three dimensional 
(3D) structure of AChE is essential. X-ray structures of AChE from different species such as 
Electrophorus electricus (eel), Torpedo californica (TcAChE), Drosophila melanogaster, human 
(hAChE) and mouse have been reported in the literature [31-32]. The structure of TcAChE provide 
insights into the mechanism of enzyme catalysis. However, recent studies have shown that the 
binding site of hAChE is different from TcAChE. Therefore, we studied the binding interactions 
of our synthesized compounds with both the enzymes by using GOLD (Genetic Optimization for 
Ligand Docking) suit v5.4.1 [33]. The X-ray crystallographic structure of TcAChE (PDB Code 
1EVE) and hAChE (PDB Code 4EY7) in complex with donepezil were used as enzyme structures. 
In general, visual inspection of the docked compound-enzyme complexes revealed following 
observations: All the docked compounds were stabilized in the cavity by forming different types 
of interactions. With few exceptions, the best-scored binding poses of compounds suggest that the 
benzene ring of quinazoline is caged into the choline binding site and forms π-π stacking 
interactions with Trp84 (Trp86 in hAChE). Phenyl ring at 2-position of the quinazoline ring 
oriented towards the peripheral anionic site (PAS) comprising Asp72, Trp279 and Tyr334 
(TcAChE numbering). Alkyl chains (methyl, ethyl and isobutyl) at 2-position of the quinazoline 
ring forms π-σ interactions with Tyr121, Phe290, Phe330, Phe331 and.Tyr334. It was also 
observed that bromine atoms of compounds 5a-h establish significant van der Waals interactions 
with Leu127, Tyr130 and Phe330. 6,8-dinitro group at quinazoline ring (4a-h) is involved in the 
hydrogen bonding interactions. Ion-dipole interactions were also observed between NH of 
quinazoline and the deprotonated aspartic acid (Asp72).  
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Superposition of the docked poses of the most active compound 5f into the binding pockets of 
TcAChE and hAChE is shown in Figure 1a. The binding mode analysis of 5f-TcAChE and 5f-
hAChE complex reveals mostly similar binding mode as shown in Figure 1a. Depiction of the 
top-scored docking pose of the most active compound 5f in the binding site of TcAChE and hAChE 
is presented in Figure 1a-b. Dibromo phenyl ring is oriented toward Trp84 (Trp86 in hAChE) and 
engaged in π-π stacking interactions. In TcAChE, two T-shaped orthogonal π-π stacking 
interactions were observed between chlorophenyl at C-2 and Phe331 and another between same 
substituent and Tyr334 (Figure 1b). Bromine atoms interacts with the π-system of  Trp84, Tyr130, 
Phe330, and His440, While, in hAChE-5f complex, chlorophenyl ring is properly packed in the 
narrow gorge and forms some π-π stacking and π-σ interactions with Tyr337 and Tyr341 
respectively. Although, the binding pattern of donepezil in hAChE is different from TcAChE [32], 
however, our small molecules bind in same conformation as in TcAChE (Figure 1a). This was 
further confirmed by their Gold fitness score values. Gold fitness score for 5f is 72.3148 (TcAChE) 
and 72.8581 (hAChE).  
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Figure 1: (a) Superimposed ribbon diagram of the top-scoring docking pose for 5f-TcAChE (red ribbons) 
and 5f-hAChE complex (blue ribbon); (b) Close-up depiction of the docking pose of compound 5f in the 
binding site of 1EVE; (c) Close-up depiction of the docking pose of compound 5f in the binding site of 
4EY7. The key residues are represented as stick model.  
The binding mode of compound 4b (IC50 = 6.2 µM) in the binding pocket of TcAChE was also 
studied. Compound 4b is embedded in the deep and narrow catalytic gorge. As depicted in Figure 
2a, oxygen atom of nitro group interact with the imidazole of His440 at a distance of 2.92 Å. Side 
chain of Asp72, one of the acidic residue present in the active site gorge, forms an ionic interaction 
with NH-quinazoline (ion-dipole interaction) at the distance of 2.12 Å. Compound 4b forms a π-π 
stacking interactions with the PAS residue Tyr334 at a distance of 4.46 Å. The backbone α-amine 
of Gly118, one of the glycine residue of oxyanion hole, forms a hydrogen bond with oxygen atom 
of nitro group. The Gold fitness score compounded for the best-scoring binding pose (Figure 2a) 
for 2f is 69.6228. Compound 3a is the least active compound with IC50 value of 80.3±1.8 µM. 
Compound 3a oriented itself at a distance of 4.36 Å and interacts with Trp84 via π-π stacking 
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interactions (Figure 2b). This only interaction is considered to be the reason of the very low 
inhibition of 3a.  
 
Figure 2: Hydrogen bond and π-π stacking interactions in the binding pocket of TcAChE (1EVE) and the 
distance (in Angstrom) of compounds; a) 4b and b) 3a 
For gaining insight into the mechanism of BChE inhibition, the X-ray crystallographic structure 
of human BChE (PDB Code 1P0I) was used as enzyme structure. The most potent BChE inhibitor 
5f displayed the most was docked into the active site of HuBChE (1P0I). The computed Gold 
fitness score of the top-scoring docking pose is 69.8391. Compound 5f displayed multiple binding pattern 
within the 5 Å distance. In the larger gorge it was engaged in π-π stacking interactions with Trp82. The 
most potent ion-dipole interaction was established between NH of the ring and deprotonated Glu197 at a 
distance of 1.58 Å. Carbonyl oxygen of the quinazoline ring established two hydrogen bond interactions 
with the backbone α-NH groups of Gly116 (1.88 Å) and Gly117 (2.91 Å). Dibromophenyl ring occupies 
hydrophobic pocket and formed π-π stacking interactions with Phe329 at a distance of 4.59 Å. 
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 Figure 3: Hydrogen bond and π-π stacking interactions of 5f in the binding pocket of human BChE (PDB 
Code 1P0I a) 3D interactions and b) 2D interactions. 
3. Conclusion 
In the light of above findings, it can be concluded that we have synthesized and tested quinazoline 
derivatives for AChE and BChE inhibitory potency. All the derivatives showed activity against 
both the enzymes. All the tested compounds showed activity against both the enzymes in 
micromolar range. In many case, the inhibition of both enzymes are higher than or comparable to 
the standard drug galatamine. The findings of this study suggest that appropriate structural 
modification of quinazoline scaffold may result in potential AChE or BChE inhibitors.  
4. Materials and Methods 
Analytical grade chemicals obtained from commercial suppliers were used as received. Melting 
points were measured using a SMP30 Stuart Scientific melting point apparatus. 1H and 13C NMR 
spectra were recorded on Bruker DRX 400 MHz NMR spectrometers. 1H and 13C chemical shifts 
are reported Vs SiMe4 and were determined by reference to the residual 1H and 13C solvent peaks. 
The X-ray diff raction data of crystals was collected on a Bruker Smart APEX II diff ractometer. 
Data reduction was carried out using the SAINT program [34]. The structure solution and 
refinements were performed with the SHELXL-2013 program package [35]. 
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4.1. General procedure for the synthesis of 2,2-disubstituted-2,3-dihydroquinazolin-4(1H)-
one (3a-h) 
Stirred solution of 2-amino benzamide (100 mmol) and ketone (200 mmol) in presence of conc. 
HNO3/ HCl (1 mL) as catalyst was refluxed for 05 minute and stirring was continued for further 
30 minutes. After completion of the reaction, product was concentrated by rotary evaporator and 
after cooling, water (20ml) was added to the mixture. Precipitates formed were filtered, washed 
with water and dried in oven. Recrystallization of the product with ethyl acetate afforded crystals 
of 2,2-disubstituted-2,3-dihydroquinazolin-4(1H)-one which were characterized by X-Rays 
crystallographic and NMR techniques. 
4.1.1. Synthesis of 2,2- dimethyl-2,3-dihydroquinazolin-4(1H)-one (3a). 
3a was synthesized by general procedure using a mixture of 2-amino benzamide (13.6 g, 
100mmol) and acetone (14.5 mL, 200 mmol) as white crystalline solid (99.5% yield), m.p. 182-
183 °C, CCDC No. 1442341. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.83 (dd, 3J = 8 Hz, 4J = 2 
Hz, 1H, ArH), 7.29-7.25 (m, 1H, ArH), 6.89 (s, 1H, NH), 6.78 (t, 3J = 8 Hz, 1H, ArH), 6.59 (d, 3J = 
8 Hz, 1H, ArH), 5.78 (s, 1H, NH), 1.37 (s, 6H, 2xCH3) ppm. 13C NMR (100 MHz, CDCl3, 25 °C): 
δ = 163.0, 147.0, 133.2, 127.2, 116.4, 114.2, 113.8, 66.8, 29.0. 
4.1.2. Synthesis of 2-methyl-2-phenyl-2,3-dihydroquinazolin-4(1H)-one(3b) 
3b was synthesized by general procedure using a mixture of 2-amino benzamide (13.6 g, 100 
mmol) and acetophenone (23.5 mL, 200 mmol) as white crystalline solid (98.2% yield). m.p. 222-
224 °C.  1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.84 (dd, 3J = 8 Hz, 4J = 2 Hz, 1H, ArH), 7.54 
(d, 3J = 8 Hz, 2H,ArH), 7.34-7.26 (m, 4H, ArH), 6.81(t, 3J = 8 Hz, 2H, NH, ArH), 6.68 (d, 3J = 8 
Hz, 1H, ArH), 5.76 (s, 1H, NH), 1.89 (s, 3H, CH3) ppm. 13C NMR (100 MHz, CDCl3, 25 °C), 
δ=164.5, 145.6, 144.7, 134.2, 128.6, 128.6, 128.5, 128.3, 125.3, 119.2, 114.9, 71.0, 29.9.  
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4.1.3. Synthesis of 2-ethyl-2-methyl-2,3-dihydroquinazolin-4(1H)-one (3c) 
3c was synthesized by general procedure using a mixture of 2-amino benzamide (13.6 g, 100 
mmol) and ethyl methyl ketone (18 mL, 200 mmol) as white crystalline solid (99.5% yield). m.p. 
179-180 °C. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.82 (dd, 3J = 8 Hz, 4J = 2 Hz, 1H, ArH), 
7.29-7.24 (m, 1H, ArH), 6.90 (s, 1H, NH), 6.80 (t, 3J = 8 Hz, 1H, ArH), 6.60 (d, 3J = 8 Hz, 1H, 
ArH), 5.76 (s, 1H, NH), 1.68-1.58 (m, 2H, CH2), 1.32 (s, 3H, CH3), 0.86 (t, 3J = 7 Hz, 3H, CH3) 
ppm. 13C NMR (100 MHz, CDCl3, 25 °C): δ = 163.1, 147.2, 133.1, 127.1, 116.0, 114.0, 113.5, 
69.2, 33.9, 27.4, 8.2. 
4.1.4. Synthesis of 2,2-diethyl-2,3-dihydroquinazolin-4(1H)-one (3d) 
3d was synthesized by general procedure using a mixture of 2-amino benzamide (13.6 g, 100 
mmol) and diethyl ketone (21.5 mL, 200 mmol) as white crystalline solid (99.5% yield); m.p. 197-
200 °C, 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.84 (dd, 3J = 8 Hz, 4J = 2 Hz, 1H, ArH), 7.29-
7.26 (m, 1H, ArH), 6.89 (s, 1H, NH), 6.77 (t, 3J = 8 Hz, 1H, ArH), 6.59 (d, 3J = 8 Hz, 1H, ArH), 
5.82 (s, 1H, NH), 1.78-1.73 (m, 4H, 2×CH2), 0.97 (t, 3J = 7 Hz, 6H, 2×CH3) ppm. 13C NMR (100 
MHz, CDCl3, 25 °C), δ=164.4, 146.2, 134.0, 128.3, 118.2, 114.1, 114.1, 72.6, 32.9, 7.9.  
4.1.5. Synthesis of 2-methyl-2-propyl-2,3-dihydroquinazolin-4(1H)-one (3e) 
3e was synthesized by general procedure using a mixture of 2-amino benzamide (13.6 g, 100 
mmol) and methyl propyl ketone (21.5 mL, 200 mmol)  as white crystalline solid (99.5% yield), 
m.p. 192-195 °C, 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.86 (dd, 3J = 8 Hz, 4J = 2 Hz, 1H, ArH), 
7.29-7.25 (m, 1H, ArH), 6.84 (s, 1H, NH), 6.80 (t, 3J = 8 Hz, 1H, ArH), 6.59 (d, 3J = 8 Hz, 1H, 
ArH), 5.87 (s, 1H, NH), 1.76-1.72 (m, 2H, CH2), 1.50 (s, 3H, CH3), 1.47-1.38 (m, 2H, CH2), 0.93 
(t, 3J = 7 Hz, 3H, CH3)  ppm. 13C NMR (100 MHz, CDCl3, 25 °C), δ=164.3, 145.9, 134, 128.3, 
118.6, 114.5, 114.4, 69.9, 44.5, 28.1, 17.2, 14.1. 
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4.1.6. Synthesis of 2-(4-chlorophenyl)-2-methyl-2,3-dihydroquinazolin-4(1H)-one (3f) 
3f was synthesized by general procedure using a mixture of 2-amino benzamide (6.8 g, 50 mmol) 
and 4-chloro acetophenone (13.0 mL, 100 mmol)  as white crystalline solid (99.5% yield). m.p. 
209-211 °C, 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.84 (dd, 3J = 8 Hz, 4J = 2 Hz, 1H, ArH), 
7.47 (d, 3J = 8 Hz, 2H, ArH), 7.33-7.27 (m, 3H, ArH), 6.92 (s, 1H, NH), 6.83 (t, 3J = 8 Hz, 1H, 
ArH), 6.67 (d, 3J = 8 Hz, 1H, ArH), 5.85 (s, 1H, NH), 1.86 (s, 3H, CH3) ppm. 13C NMR (100 MHz, 
CDCl3, 25 °C), δ=164.0, 145.3, 143.5, 134.3, 128.8, 128.7, 128.5, 126.8, 119.6, 115.1, 70.6, 30.0. 
4.1.7. Synthesis of 2-methyl-2-(2-methylpropyl)-2,3-dihydroquinazolin-4(1H)-one (3g) 
3g was synthesized by general procedure using a mixture of 2-amino benzamide (13.6 g, 100 
mmol) and methyl isobutyl ketone (25 mL, 200 mmol) as white crystalline solid (99.2% yield). 
m.p. 170-172 °C. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.86 (dd, 3J = 8 Hz, J = 2 Hz, 1H, ArH), 
7.32-7.27 (m, 1H, ArH), 6.92 (s, 1H, NH), 6.81 (t, 3J = 8 Hz, 1H, ArH), 6.62  (d, 3J = 8 Hz, 1H, 
ArH), 5.81 (s, 1H, NH), 1.94-1.88 (m, 1H, CH), 1.70 (d, 3J = 6 Hz, 2H, CH2), 1.54 (s, 3H, CH3), 
0.97 (t, 3J = 7 Hz, 6H, 2×CH3)  ppm. 13C NMR (100 MHz, CDCl3, 25 °C), δ=164.4, 145.9, 133.9, 
128.3, 118.4, 114.5, 114.4, 70.2, 50.3, 28.8, 24.5, 24.3, 24.1. 
4.1.8. Synthesis of 2,2-bis(2-methylpropyl)-2,3-dihydroquinazolin-4(1H)-one (3h) 
3h was synthesized by general procedure using a mixture of 2-amino benzamide (6.8 g, 50 mmol) 
and diisobutyl ketone (17.5 mL, 100 mmol) as white crystalline solid (99.5% yield). m.p. 170-172 
°C. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.83 (dd, 3J = 8 Hz, 4J = 2 Hz, 1H, ArH), 7.33-7.28 
(m, 1H, ArH), 6.89 (s, 1H, NH), 6.78 (t, 3J = 8 Hz, 1H, ArH), 6.60  (d, 3J = 8 Hz, 1H, ArH), 5.78 
(s, 1H, NH), 1.92-1.85 (m, 2H, 2×CH), 1.74 (d, 3J = 6 Hz, 2H, CH2), 1.71 (d, 3J = 6 Hz, 2H, CH2),  
0.96 (d, 3J = 7 Hz, 6H, 2×CH3), 0.94 (d, 3J = 7 Hz, 6H, 2×CH3)  ppm. 13C NMR (100 MHz, CDCl3, 
25 °C), δ=164.6, 143.9, 133.9, 128.3, 117.8, 114.5, 115.4, 68.9, 52.3, 24.6, 24.3, 21.4. 
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4.2. General Procedure for the synthesis of 6,8-dinitro-2,2-disubstituted-2,3-
dihydroquinazolin-4(1H)-one (4a-h) 
Above synthesized 2,3-disubstituted quinazoline (3a-h) (0.01 mole) was added to conc. H2SO4 
(10mL) and stirred to dissolve in an ice bath. To this solution conc. HNO3 (0.5mL) was added drop 
wise and stirring was continued for further 6 hours. Mixture was poured on crushed ice and left 
overnight. Precipitates formed were filtered and washed with plenty of water, dried in oven and 
recrystallized from ethanol to afford yellowish crystals of 6,8-dinitro-2,2-disubstituted-2,3-
dihydroquinazolin-4(1H)-one which were further characterized by NMR and XRD techniques.  
4.2.1. Synthesis of 6,8-dinitro-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-one (4a). 
Yellow crystalline solid.  1H NMR (400 MHz, CDCl3, 25 °C): δ = 9.22 (d, 3J = 8 Hz, 1H, ArH), 
9.02 (d, 3J = 8 Hz, 1H, ArH), 6.90 (s, 1H, NH), 5.80 (s, 1H, NH), 1.38 (s, 6H, 2×CH3) ppm. 13C 
NMR (100 MHz, CDCl3,25 °C), δ=161.2, 144.8, 130.6, 128.3, 128.5, 125.5, 121.7, 67.4, 31.6. 
4.2.2. Synthesis of 2-methyl-6,8-dinitro-2-(3-nitro-phenyl)-2,3-dihydro-1H-quinazolin-4-one 
(4b) 
Yellow crystalline solid.CCDC 1509031.1H NMR (400 MHz, CDCl3, 25 °C): δ = 9.23 (d, 3J = 8 
Hz, 1H, ArH), 9.06 (d, 3J = 8 Hz, 1H, ArH), 8.22 (d, 3J = 8 Hz, 2H, ArH), 7.81 (d, 3J = 8 Hz, 2H, 
ArH), 6.90 (s, 1H, NH), 5.83 (s, 1H, NH), 1.85 (s, 3H, CH3) ppm. 
4.2.3. Synthesis of 6,8-dinitro-2-ethyl, 2-methyl-2,3-dihydroquinazolin-4(1H)-one (4c) 
Yellow crystalline solid. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 9.21 (d, 3J = 8 Hz, 1H, ArH), 
9.02 (d, 3J = 8 Hz, 1H, ArH), 6.91 (s, 1H, NH), 5.78 (s, 1H, NH), 1.99-1.93 (m, 2H, CH2), 1.24 (s, 
3H, CH3), 1.04 (t, 3J = 7 Hz, 3H, CH3) ppm.  
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4.2.4. Synthesis of 6,8-dinitro-2,2-diethyl-2,3-dihydroquinazolin-4(1H)-one (4d) 
Yellow crystalline solid.1H NMR (400 MHz, CDCl3, 25 °C): δ = 9.21 (d, 3J = 8 Hz, 1H, ArH), 9.02 
(d, 3J = 8 Hz, 1H, ArH), 6.92 (s, 1H, NH), 5.67 (s, 1H, NH), 1.95-1.88 (m, 4H, 2×CH2), 1.05 (t, 3J 
= 7 Hz, 6H, 2×CH3) ppm. 13C NMR (100 MHz, CDCl3, 25 °C), δ=160.2, 145.8, 130.6, 130.3, 128.5, 
127.3, 122.0, 74.6, 32.2, 7.6. 
4.2.5. Synthesis of 6,8-dinitro-2-methyl-2-propyl-2,3-dihydroquinazolin-4(1H)-one (4e) 
Yellow crystalline solid. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 9.22 (d, 3J = 8 Hz, 1H, ArH), 
9.03 (d, 3J = 8 Hz, 1H, ArH), 6.91 (s, 1H, NH), 5.84 (s, 1H, NH), 1.75-1.72 (m, 2H, CH2), 1.51 (s, 
3H, CH3), 1.47-1.38 (m, 2H, CH2), 0.93 (t, 3J = 7 Hz, 3H, CH3) ppm. 13C NMR (100 MHz, CDCl3, 
25 °C), δ=161.2, 145.6, 131.6, 130.8, 128.7, 124.9, 121.3, 71.4, 44.8, 28.4, 16.9, 14.5. 
4.2.7. Synthesis of 6,8-dinitro-2-methyl-2-(2-methylpropyl)-2,3-dihydroquinazolin-4(1H)-one 
(4g) 
Yellow crystalline solid. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 9.21 (d, 3J = 8 Hz, 1H, ArH), 
9.04 (d, 3J = 8 Hz, 1H, ArH), 6.88 (s, 1H, NH), 5.86 (s, 1H, NH), 1.95-1.88 (m, 1H, CH), 1.85 (d, 
3J = 6 Hz, 2H, CH2), 1.72 (s, 3H, CH3), 1.02 (d, 3J = 6 Hz, 6H, 2×CH2) ppm. 13C NMR (100 MHz, 
CDCl3, 25 °C), δ=160.1, 145.0, 136.7, 130.9, 130.4, 127.3, 116.9, 71.5, 51.5, 30.7, 24.2, 24.0. 
4.2.8. Synthesis of 6,8-dinitro-2,2-bis(2-methylpropyl)-2,3-dihydroquinazolin-4(1H)-one (4h) 
Yellow crystalline solid. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 9.21 (d, 3J = 8 Hz, 1H, ArH), 
9.05 (d, 3J = 8 Hz, 1H, ArH), 6.92 (s, 1H, NH), 5.86 (s, 1H, NH), 1.91-1.85 (m, 2H, 2×CH), 1.74 
(d, 3J = 6 Hz, 2H, CH2), 1.71 (d, 3J = 6 Hz, 2H, CH2),  0.96 (d, 3J = 6 Hz, 6H, 2×CH3), 0.94 (d, 3J 
= 6 Hz, 6H, 2×CH3)  ppm. 13C NMR (100 MHz, CDCl3, 25 °C), δ=160.4, 145.2, 136.2, 131.4, 
130.7, 126.6, 117.2, 69.3, 52.8, 24.8, 24.6, 20.8. 
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4.3. Synthesis of 6,8-dibromo-2,2-disubstituted-2,3-dihydroquinazolin-4(1H)-one (5a-h) 
To a stirred solution of 2,2-disubstituted quinazoline (10 mmol) and KBrO3 (10 mmol) in 
acetonitrile (10ml) was added dil. HCl (10 mL, 1N) drop wise and stirring was continued for 6 hrs 
at 70 oC. Concentration of the mixture was done at rotary evaporator and washing was done with 
water. Recrystallization of the product with ethanol resulted required product. 
4.3.1. Synthesis of 6,8-dbromo-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-one (5a). 
Brownish crystalline solid. CCDC 1442364.1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.85 (d, 3J = 
8 Hz, 1H, ArH), 7.55 (d, 3J = 8 Hz, 1H, ArH), 6.90 (s, 1H, NH), 5.86 (s, 1H, NH), 1.41 (s, 6H, 
2×CH3) ppm. 
4.3.2. Synthesis of 6,8-dibromo-2-methyl-2-phenyl-2,3-dihydroquinazolin-4(1H)-one (5b) 
Brownish crystalline solid. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.87 (d, 3J = 8 Hz, 1H, ArH), 
7.63 (d, 3J = 8 Hz, 1H, ArH), 7.24 (d, 3J = 8 Hz,  2H, ArH), 7.14 (d, 3J = 7 Hz, 2H, ArH), 6.93 (s, 
1H, NH), 5.86 (s, 1H, NH), 1.89 (s, 3H, CH3) ppm 
4.3.3. Synthesis of 6,8-dibromo-2-ethyl, 2-methyl-2,3-dihydroquinazolin-4(1H)-one (5c) 
Brownish crystalline solid. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.83 (d, 3J = 8 Hz, 1H, ArH), 
7.53 (d, 3J = 8 Hz, 1H, ArH), 6.89 (s, 1H, NH), 5.78 (s, 1H, NH), 1.84-1.83 (m, 2H, CH2), 1.49 (s, 
3H, CH3), 1.25 (t, 3J = 7 Hz, 3H, CH3) ppm. 
4.3.4. Synthesis of 6,8-dibromo-2,2-diethyl-2,3-dihydroquinazolin-4(1H)-one (5d) 
Brownish crystalline solid.1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.81 (d, 3J = 8 Hz, 1H, ArH), 
7.63 (d, 3J = 8 Hz, 1H, ArH), 6.91 (s, 1H, NH), 5.80 (s, 1H, NH), 1.79-1.74 (m, 4H, 2×CH2), 0.97 
(t, 3J = 7 Hz, 6H, 2×CH3) ppm. 
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4.3.5. Synthesis of 6,8-dibromo-2-methyl-2-propyl-2,3-dihydroquinazolin-4(1H)-one (5e) 
Brownish crystalline solid.1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.86 (d, 3J = 8 Hz, 1H, ArH), 
7.38 (d, 3J = 8 Hz, 1H, ArH), 6.94 (s, 1H, NH), 5.82 (s, 1H, NH), 1.75-1.69 (m, 2H, CH2), 1.49 (s, 
3H, CH3), 1.46-1.40 (m, 2H, CH2), 0.93 (t, 3J = 7 Hz, 3H, CH3) ppm. 
4.3.6. Synthesis of 6,8-Dibromo-2-(3-bromo-4-chloro-phenyl)-2-methyl-2,3-dihydro-1H-
quinazolin-4-one (5f) 
Brownish crystalline solid. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.89 (d, 3J = 8 Hz, 1H, ArH), 
7.68 (d, 3J = 8 Hz, 1H, ArH), 7.35 (s, 1H, ArH), 7.19 (d, 3J = 7 Hz, 1H, ArH), 7.08 (d, 3J = 7 Hz, 
1H, ArH), 6.89 (s, 1H, NH), 5.86 (s, 1H, NH), 1.89 (s, 3H, CH3) ppm. 
4.3.7. Synthesis of 6,8-dibromo-2-methyl-2-(2-methylpropyl)-2,3-dihydroquinazolin-4(1H)-one 
(5g) 
Brownish crystalline solid. 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.87 (d, 3J = 8 Hz, 1H, ArH), 
7.68 (d, 3J = 8 Hz, 1H, ArH), 6.93 (s, 1H, NH), 5.85 (s, 1H, NH), 1.94-1.88 (m, 1H, CH), 1.85 (d, 
3J = 6 Hz, 2H, CH2), 1.73 (s, 3H, CH3), 1.04 (d, 3J = 6 Hz, 6H, 2×CH3) ppm. 
4.3.8. Synthesis of 6,8-dibromo-2,2-bis(2-methylpropyl)-2,3-dihydroquinazolin-4(1H)-one (5h) 
Brownish crystalline solid.1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.88 (d, 3J = 8 Hz, 1H, ArH), 
7.67 (d, 3J = 8 Hz, 1H, ArH), 6.91 (s, 1H, NH), 5.82 (s, 1H, NH), 1.92-1.84 (m, 2H, 2 × CH), 1.73 
(d, 3J = 7 Hz, 2H, CH2), 1.71 (d, 3J = 7 Hz, 2H, CH2),  0.98 (d, 3J = 6 Hz, 6H, 2×CH3), 0.96 (d, 3J 
= 6 Hz, 6H, 2×CH3)  ppm. 
4.4. Determination of AChE and BChE inhibitory activity 
AChE (Electric eel type-VI-S, Sigma-Aldrich GmbH USA, code 1001596210), BChE (Equine 
serum Lyophilized Sigma-Aldrich GmbH USA, code 101292670), Acetylthiocholine iodide 
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(Sigma-Aldrich UK, code 101303874), Butyrylthiocholine Iodide (Sigma-Aldrich Switzerland, 
code 101334643), DTNB (Sigma-Aldrich Germany, code 101261619), Galantamine hydrobromide 
Lycoris Sp. (Sigma-Aldrich France, code G1660). All the other chemicals used were of analytical 
grade. 
Galantamine was used as reference drugs. The synthesized quinazolines were dissolved in 0.1 M 
phosphate buffer of pH 8.0. (KH2PO4/K2HPO4. The reaction mixture consisted of appropriate 
amount of, DTNB (Ellman’s reagent), test compounds, of 0.03 U/ml of enzymes (AChE and BChE). 
The mixture was pre-incubated at 30 °C for 10 min and followed by adding 1mM ATCI or BTCI 
and incubated again for 15 min. The enzymatic hydrolysis was monitored at 412 nm using µQuant 
microplate spectrophotometer (MQX200, BioTek USA). All reactions were carried out in triplicate. 
The IC50 values were determined by plotting the inhibition against the sample solution 
concentrations.  
4.5. Computational studies 
Docking studies were carried out using GOLD (Genetic Optimization for Ligand Docking) suit 
v5.4.1. The X-ray crystallographic structure TcAChE (PDB Code 1EVE) and hAChE (PDB Code 
4EY7) and human BChE (PDB Code 1P0I) was used as enzyme structures. The default docking 
protocol was applied and the synthesized tin complexes were submitted to 10 GA runs using 
GOLD fitness score. Other docking parameters were set to the software’s default values. The view 
of the docking results and analysis of their surface with graphical representations were done using 
Discovery Studio Visualizer [36] and Chimera 1.11.2rc [37]. 
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